Healios KK (JP:4593) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Healios K.K. has reached a key milestone in their joint research with AND medical, securing a 60 million yen payment as part of an ongoing agreement focused on producing culture supernatant using Healios’ technology. The company anticipates beginning monthly supply of 25 liters of culture supernatant to AND medical in fiscal year 2025, with the possibility of increasing production based on demand. This collaboration aims to advance regenerative medicine, with Healios providing its expertise in stem cell technology for new therapy development.
For further insights into JP:4593 stock, check out TipRanks’ Stock Analysis page.